Compare Regeneron Pharmaceuticals Inc (REGN) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs TJX Companies Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B), while TJX Companies Inc trades at $126.32 (market cap $141.81B). The key difference: TJX Companies Inc is the larger of the two by market cap, and TJX Companies Inc pays the higher dividend (1.49%). Which is the better fit depends on your goals.
| REGN | TJX | |
|---|---|---|
Market Cap | $83.43B | $141.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $852.03 | $168.41 |
52-Week Low | $555.51 | $126.10 |
Enterprise Value | $78.14B | $150.12B |
Dividend Yield | 0.46% | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
TJX Companies (TJX) trades at $128.91, down 2.4% over 24 hours, with technical indicators showing bearish momentum but oversold RSI signals. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.22 exceeding expectations. Revenue grew to $56.36 billion in 2025, and net income margin improved to 9.73%. Analysts maintain a bullish consensus with 84.6% buy ratings and a $169 price target, citing expansion plans to 7,500 stores.
The outlook for TJX is positive due to consistent earnings outperformance and robust store growth strategy, though near-term stock pressure reflects valuation concerns and competitive comparisons. Key risks include market volatility and execution challenges in scaling operations. Investors may find opportunity in the current dip given strong fundamentals and analyst support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
